Skip to content

Patients

If you are interested in learning more about participating in the ABS-1230 Phase 1b/2 clinical trial, please visit ActioTrials.com, where you can find details about current studies, eligibility, and trial locations.

KCNT1 Epilepsy Foundation

For more information about KCNT1-related epilepsy, new therapies in development, the latest research information and resources for families and caregivers, please visit the KCNT1 Epilepsy Foundation website. The Foundation provides educational materials and a supportive community for families navigating this rare disease.  

Kyron Logo

Expanded Access Policy

Our purpose at Actio Biosciences, Inc. is to develop new therapies that have a positive impact on patient health, and to serve patients, patient families and patient communities through education, empathy, and awareness. Read more…

Actio is now part of Jazz Pharmaceuticals

Select Jazz for more information about Jazz Pharmaceuticals.

Select continue to proceed to the Actio website.

Jazz